Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 19, 2019. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific share transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a non-monetary transfer of shares between accounts.
Transaction Details and Commentary
- Transaction Date: February 18, 2019.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Parties Involved:
- Transferor: Ms. E. Walmsley (Chief Executive Officer).
- Transferee: Mr. David Owen (Person Closely Associated with Ms. Walmsley, identified as spouse).
- Nature of Transaction: Transfer of 102,035 Ordinary Shares for nil consideration (£0.00).
- Beneficial Ownership: The filing explicitly states there was no change in beneficial ownership.
Investor Verification Checklist
- Verify the total shareholding of Ms. E. Walmsley and Mr. David Owen following this transfer to confirm the "no change in beneficial ownership" claim.
- Confirm that this transaction was not part of a broader divestment or compensation restructuring plan not detailed in this specific form.
- Check subsequent filings for any related transactions involving the same parties within the reporting window.